MedTrace Logo

Ocular Hypertension Treatment Study (OHTS)

NCT00000125 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1636

Last updated 2020-06-02

Study results available
· View outcomes & findings →

Summary

To determine whether medical reduction of intraocular pressure prevents or delays the onset of glaucomatous visual field loss and/or optic disc damage in ocular hypertensive participants judged to be at moderate risk for developing open-angle glaucoma.

To produce natural history data to assist in identifying patients at most risk for developing open-angle glaucoma and those most likely to benefit from early medical treatment.

To quantify risk factors for developing open-angle glaucoma among ocular hypertensive individuals.

Conditions

Interventions

DRUG

Topical ocular hypotensive eye drops.

Topical ocular hypotensive eye drops.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Michael A Kass, MD · Washington University Department of Ophthalmology and Visual Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-02-28
Primary Completion
2002-06-30
Completion
2019-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000125 on ClinicalTrials.gov